Publication

Article

Pharmacy Times

September 2013 Oncology
Volume79
Issue 9

NCCN Guidelines May Improve Ovarian Cancer Outcomes

Ovarian cancer patients who receive care that coincides with the National Comprehensive Cancer Network (NCCN) guidelines may have an increased chance of survival, according to the results of a recent study published in the July 2013 issue of Gynecologic Oncology.

The study enrolled 13,321 patients from the California Cancer Registry diagnosed with epithelial ovarian cancer between 1999 and 2006 who were receiving surgical treatment. Treatment was considered to be adherent to NCCN guidelines if it followed stage-appropriate surgical procedures and recommended chemotherapy. The researchers studied patient, disease-related, and treatment characteristics related to guideline adherence and overall survival.

Overall, 37.2% of patients received care adherent to NCCN guidelines. After adjusting for disease-related and health care system factors, patients who received treatment nonadherent to NCCN guidelines were 34% more likely to die of ovarian cancer than those who received adherent care. High-volume hospitals, those that treated 20 or more cases of ovarian cancer per year, were likely to deliver guideline-adherent care 50.8% of the time, while low-volume hospitals were adherent to guidelines just 34.1% of the time. Surgeons who operated on at least 10 ovarian cancer patients per year were more likely to be adherent to guidelines than low-volume surgeons: 47.6% compared with 34.5%, respectively.

The authors conclude that adherence to NCCN guidelines may improve the chances for survival in ovarian cancer patients.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com